Monoclonal antibodies for the prevention and treatment of graft-versus-host disease

Seminars in Oncology

Volumn 30, Issue 4, 2003, Pages 509-519

  Bruner, Rebecca J ^b   Farag, Sherif S ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CAMPATH 1G; CAMPATH 1M; CD5 ANTIGEN IMMUNOTOXIN; CELL ADHESION MOLECULE; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; DENILEUKIN DIFTITOX; ETANERCEPT; FAS LIGAND; FLUDARABINE; GAMMA INTERFERON ANTIBODY; IMMUNOTOXIN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ABX CBL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PROTEIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

ALLOTRANSPLANTATION; CHILL; CLINICAL TRIAL; DIAPHORESIS; DOSE RESPONSE; DRUG SCREENING; DRUG SPECIFICITY; DRUG TARGETING; FEVER; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC ANEMIA; HUMAN; IMMUNOPATHOLOGY; MORBIDITY; MYALGIA; MYCOSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SERUM SICKNESS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 0041736016     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00250-1     Document Type: Article

References (101)

1. Biggs JC, Szer J, Crilley P, et al: Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 80:1352-1357, 1992
2. Chao NJ, Schmidt GM, Niland JC, et al: Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329:1225-1230, 1993
3. Socie G, Stone J, Wingard J, et al: Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 341:14-21, 1999
4. Martin PJ, Schoch G, Fisher L, et al: A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment. Blood 77:1821-1828, 1991
5. Hings IM, Severson R, Filipovich AH, et al: Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 58:437-442, 1994
6. Goker H, Haznedaroglu IC, Chao NJ: Acute graft-vs-host disease: Pathobiology and management. Exp Hematol 29:259-277, 2001
7. Vogelsang GB: Advances in the treatment of graft-versus-host disease. Leukemia 14:509-510, 2000
8. Jacobsohn DA: Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin Invest Drugs 11:1271-1280, 2002
9. Ferrara JL, Levy R, Chao N: Pathophysiologic mechanisms of acute graft-vs-host disease. Biol Blood Marrow Transplant 5:347-356, 1999
10. Xun CQ, Thompson JS, Jennings CD, et al: Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83:2360-2367, 1994
11. Alegre ML, Frauwirth KA, Thompson CB: T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1:220-228, 2001
12. Butcher EC, Picker LJ: Lymphocyte homing and homeostasis. Science 272:60-66, 1996
13. Guinan EC, Boussiotis VA, Neuberg D, et al: Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 340:1704-1714, 1999
14. Seung E, Iwakoshi N, Woda BA, et al: Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: Absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 95:2175-2182, 2000
15. Stoppa AM, Maraninchi D, Blaise D, et al: Anti-LFA1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III-IV acute graft-versus-host disease. Transplant Int 4:3-7, 1991
16. Anasetti C, Martin PJ, Hansen JA, et al: A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation 50:49-54, 1990
17. Anasetti C, Hansen JA, Waldmann TA, et al: Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 84:1320-1327, 1994
18. Herve P, Wijdenes J, Bergerat JP, et al: Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 75:1017-1023, 1990
19. Przepiorka D, Phillips GL, Ratanatharathorn V, et al: A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 92:4066-4071, 1998
20. Przepiorka D, Kernan NA, Ippoliti C, et al: Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95:83-89, 2000
21. LeMaistre CF: DAB(389)IL-2 (dineleukin difitox, ON-TAK): Other potential applications. Clin Lymphoma 1:S37-40, 2000 (suppl 1)
22. Shlomchik WD, Couzens MS, Tang CB, et al: Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285:412-415, 1999
23. Holler E, Kolb HJ, Mittermuller J, et al: Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 86:890-899, 1995
24. Herve P, Racadot E, Wijdenes J, et al: Monoclonal anti TNF alpha antibody in the treatment of acute GvHD refractory both to corticosteroids and anti IL-2R antibody. Bone Marrow Transplant 7:149, 1991 (suppl 2)
25. Tsimberidou AM, Giles FJ: TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther 2:277-286, 2002
26. Cooke KR, Gerbitz A, Crawford JM, et al: LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 107:1581-1589, 2001
27. Miwa K, Hashimoto H, Yatomi T, et al: Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease. Int Immunol 11:925-931, 1999
28. + helper cells. Transplantation 60:481-490, 1995
29. Sykes M, Szot GL, Nguyen PL, et al: Interleukin-12 inhibits murine graft-versus-host disease. Blood 86:2429-2438, 1995
30. Hill GR, Cooke KR, Teshima T, et al: Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 102:115-123, 1998
31. Storb R, Deeg HJ, Whitehead J, et al: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729-735, 1986
32. Storb R, Deeg HJ, Pepe M, et al: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 73:1729-1734, 1989
33. Mrsic M, Labar B, Bogdanic V, et al: Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 6:137-141, 1990
34. Ringden O, Klaesson S, Sundberg B, et al: Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Bone Marrow Transplant 9:19-25, 1992
35. Chao N, Snyder D, Jain M: Equivalence of two effective GVHD prophylaxis regimens: Results of a prospective blinded randomized trial. Blood 94:2957a, 1999 (suppl 1, abstr)
36. Nash RA, Antin JH, Karanes C, et al: Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96:2062-2068, 2000
37. Ratanatharathorn V, Nash RA, Przepiorka D, et al: Phase III study comparing methotrexate and tacrolimus (pro-graf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92:2303-2314, 1998
38. Basara N, Blau WI, Kiehl MG, et al: Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant 14:121-126, 2000
39. Chen BJ, Morris RE, Chao NJ: Graft-versus-host disease prevention by rapamycin: Cellular mechanisms. Biol Blood Marrow Transplant 6:529-536, 2000
40. Doney KC, Storb R, Beach K, et al: A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. Transplantation 60:55-58, 1995
41. Schlegel PG, Aharoni R, Chen Y, et al: A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proc Natl Acad Sci USA 93:5061-5066, 1996
42. Bolanos-Meade J, Jacobsohn D, Margolis J, et al: Pentostatin in steroid refractory acute graft versus host disease. Blood 100:420a, 2002 (suppl 1, abstr)
43. Hows J, Bradley BA, Gore S, et al: Prospective evaluation of unrelated donor bone marrow transplantation. The International Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant 12:371-380, 1993
44. Byrne JL, Stainer C, Cull G, et al: The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant 25:411-417, 2000
45. Finke J, Bertz H, Schmoor C, et al: Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol 111:303-313, 2000
46. Hansen JA, Gooley TA, Martin PJ, et al: Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962-968, 1998
47. Sierra J, Storer B, Hansen JA, et al: Unrelated donor marrow transplantation for acute myeloid leukemia: An update of the Seattle experience. Bone Marrow Transplant 26:397-404, 2000
48. Kroger N, Zabelina T, Kruger W, et al: Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Hematol 80: 209-215, 2001
49. Bacigalupo A, Lamparelli T, Bruzzi P, et al: Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98:2942-2947, 2001
50. Filipovich AH, McGlave PB, Ramsay NK, et al: Pre-treatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet 1:1266-1269, 1982
51. Mitsuyasu RT, Champlin RE, Gale RP, et al: Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med 105:20-26, 1986
52. Antin JH, Bierer BE, Smith BR, et al: Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: Effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 78: 2139-2149, 1991
53. Prentice HG, Blacklock HA, Janossy G, et al: Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1:472-476, 1984
54. Goldman JM, Gale RP, Horowitz MM, et al: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806-814, 1988
55. Buggins AGS, Fishlock K, Westwood NB, et al: Peripheral blood cells with the phenotype and function of myeloid dendritic cells express CD52 and are depleted during therapy with CAMPATH-1H. Br J Haematol 117:53, 2002 (suppl 1, abstr)
56. Hale G, Zhang MJ, Bunjes D, et al: Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 92:4581-4590, 1998
57. Hale G, Jacobs P, Wood L, et al: CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 26:69-76, 2000
58. Kottaridis PD, Milligan DW, Chopra R, et al: In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96:2419-2425, 2000
59. Perez-Simon JA, Kottaridis PD, Martino R, et al: Non-myeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100:3121-3127, 2002
60. Van Lint MT, Uderzo C, Locasciulli A, et al: Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 92:2288-2293, 1998
61. Doney KC, Weiden PL, Storb R, et al: Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplantation 31:141-143, 1981
62. Cahn JY, Bordigoni P, Tiberghien P, et al: Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 60:939-942, 1995
63. Martin PJ, Nelson BJ, Appelbaum FR, et al: Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 88:824-830, 1996
64. Weisdorf D, Haake R, Blazar B, et al: Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome. Blood 75:1024-1030, 1990
65. Roy J, McGlave PB, Filipovich AH, et al: Acute graft-versus-host disease following unrelated donor marrow transplantation: Failure of conventional therapy. Bone Marrow Transplant 10:77-82, 1992
66. Dugan MJ, DeFor TE, Steinbuch M, et al: ATG plus corticosteroid therapy for acute graft-versus-host disease: Predictors of response and survival. Ann Hematol 75:41-46, 1997
67. Remberger M, Aschan J, Barkholt L, et al: Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 15:147-153, 2001
68. Khoury H, Kashyap A, Adkins DR, et al: Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 27:1059-1064, 2001
69. Arai S, Margolis J, Zahurak M, et al: Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 8:155-160, 2002
70. Mollee P, Morton AJ, Irving I, et al: Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. Br J Haematol 113:217-223, 2001
71. MacMillan ML, Weisdorf DJ, Davies SM, et al: Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 8:40-46, 2002
72. Al-Ghamdi H, Leisenring W, Bensinger WI, et al: A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest. Br J Haematol 113:461-469, 2001
73. Hsu B, May R, Carrum G, et al: Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: An international practice survey. Bone Marrow Transplant 28:945-950, 2001
74. Kiehl MG, Schafer-Eckart K, Kroger M, et al: Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. Transplant Proc 34: 2922-2924, 2002
75. Basara N, Kiehl MG, Blau W, et al: Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: Four years of experience. Transplant Proc 33:2121-2123, 2001
76. Antin JH, Weinstein HJ, Guinan EC, et al: Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84:1342-1348, 1994
77. Andolina M, Rabusin M, Maximova N, et al: Etanercept in graft-versus-host disease. Bone Marrow Transplant 26:929a, 2000 (abstr)
78. Srinivasan R, Geller N, Chakrabarti S, et al: High response rate and improved survival in patients with steroid-refractory acute graft-vs-host disease (SRGVHD) treated with daclizumab with or without infliximab. Blood 100:173-174a, 2002 (suppl 1, abstr)
79. Depper JM, Leonard WJ, Kronke M, et al: Regulation of interleukin 2 receptor expression: Effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J Immunol 133:3054-3061, 1984
80. Willenbacher W, Basara N, Blau IW, et al: Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 112:820-823, 2001
81. Cole MS, Stellrecht KE, Shi JD, et al: HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenecity in vivo. Transplantation 68:563-571, 1999
82. Carpenter PA, Appelbaum FR, Corey L, et al: A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99:2712-2719, 2002
83. Kobbe G, Schneider P, Rohr U, et al: Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 28:47-49, 2001
84. Fuchs M, Waldschmidt D, Scheid C, et al: Anti TNF-alpha antibody in the treatment of severe acute graft versus host disease. Blood 98:356b, 2001 (suppl 1, abstr 5198)
85. Magalhaes-Silverman M, Lee C, Hohl R, et al: Treatment of severe steroid refractory acute graft versus host disease with infliximab. Blood 98:359b, 2001 (suppl 1, abstr 5208)
86. Redei I, Knoche J, Tanner A, et al: Salvage therapy with infliximab for patients with severe acute and chronic GVHD. Blood 100:835a, 2002 (suppl 1, abstr)
87. Trenschel R, Ditschkowski M, Biersack H, et al: Infliximab as treatment for steroid refractory acute and chronic graft-versus-host disease. Blood 100:450b, 2002 (suppl 1, abstr)
88. Couriel D, Hicks K, Ippoliti C, et al: Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: An update. Blood 96:400a, 2000 (suppl 1, abstr)
89. Marty F, Lee S, Alyea E, et al: Risk of non-candida invasive fungal infections in allogeneic bone marrow transplant patients who received infliximab to control severe graft versus host disease. Blood 100:628-629a, 2002 (suppl 1, abstr)
90. Koch C, Staffler G, Huttinger R, et al: T cell activation-associated epitopes of CD147 in regulation of the T cell response, and their definition by antibody affinity and antigen density. Int Immunol 11:777-786, 1999
91. Deeg HJ, Blazar BR, Bolwell BJ, et al: Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 98:2052-2058, 2001
92. Ho V, Zarieh D, Neuberg D, et al: Safety and efficacy of denileukin difitox (ONTAK) in patients with steroid refractory graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 100:423a, 2002 (suppl 1, abstr)
93. van Oosterhout YV, van Emst L, Schattenberg AV, et al: A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease. Blood 95:3693-3701, 2000
94. Urra JM, Arteta M, Gomez-Caturla A, et al: A chimeric anti-TNFalpha monoclonal antibody (cA2) in vivo removes TNFalpha-producing cells in Crohn's disease. Hum Antibodies 10:91-94, 2001
95. Vogelsang G: Acute and chronic graft-versus-host disease. Curr Opin Oncol 5:276-281, 1993
96. Ochs LA, Blazar BR, Roy J, et al: Cytokine expression in human cutaneous chronic graft-versus-host disease. Bone Marrow Transplant 17:1085-1092, 1996
97. Barak V, Levi-Schaffer F, Nisman B, et al: Cytokine dysregulation in chronic graft versus host disease. Leuk Lymphoma 17:169-173, 1995
98. Vogelsang GB: How I treat chronic graft-versus-host disease. Blood 97:1196-1201, 2001
99. Couriel D, Saliba R, Hicks K, et al: TNF-alpha inhibition for the treatment of chronic GVHD. Blood 100:847a, 2002 (suppl 1, abstr)
100. Abhyankar S, Day S, Barnhart C, et al: Daclizumab (DAC)+-mycophenolate mofetil (MMF) for control of graft-versus-host disease (GVHD) in allogeneic stem cell transplant patients with cyclosporine of tacrolimus intolerance. Blood 100:445b, 2002 (suppl 1, abstr)
101. Wolff D, Steiner B, Kleine H, et al: Treatment of steroid resistant acute GVHD with daclizumab and etanercept. Blood 100:421a, 2002 (suppl 1, abstr)